Multivariate analysis of factors associated with resolution versus non-resolution of acute cholecystitis
| Resolution | No resolution | N | P value | OR | 95% CI | |
| Total N | 157 | 29 | 186 | |||
| PCT | 51 (94%) | 3 (5.6%) | 54 | 0.03 | 4.89 | 1.18 to 20.2 |
| Age (years), median (IQR) | 57 (44–63) | 55 (43–65) | 132 | 0.36 | 1.02 | 0.98 to 1.05 |
| Sex (male) | 54 (78%) | 15 (22%) | 69 | 0.26 | 0.57 | 0.21 to 1.52 |
| Abdominal malignancy | 36 (92%) | 3 (7.7%) | 39 | 0.02 | 6.66 | 1.36 to 32.6 |
| Abdominal radiation | 4 (57%) | 3 (34%) | 7 | 0.01 | 0.09 | 0.02 to 0.53 |
| Hematologic malignancy | 52 (74%) | 18 (26%) | 70 | 0.36 | 1.83 | 0.50 to 6.76 |
| Chemo<6 weeks | 59 (80%) | 15 (20%) | 74 | 0.68 | 0.81 | 0.30 to 2.18 |
| Stem cell transplant | 26 (20%) | 10 (7.6%) | 36 | 0.97 | 0.98 | 0.26 to 3.73 |
| ANC (1000 cells/μL), median (IQR) | 3.5 (2.2–6.1) | 2.6 (1.1–6.2) | 125 | 0.87 | 0.98 | 0.90 to 1.06 |
| Steroids | 18 (82%) | 4 (18%) | 22 | 0.95 | 0.92 | 0.07 to 11.3 |
| Length of stay (days), median (IQR) | 7 (4–15) | 6 (3–10) | 186 | 0.02 | 0.97 | 0.94 to 0.99 |
| ASA III | 99 (63%) | 20 (69%) | 119 | 0.24 | 0.45 | 0.12 to 1.69 |
Chemo<6 weeks indicates chemotherapy received less than 6 weeks to presentation.
Area under the curve=0.78.
ANC, absolute neutrophil count; ASA, American Society of Anesthesiologists; PCT, percutaneous cholecystostomy tube.